Stoke Therapeutics Share Price Today

Stoke Therapeutics presents STK-002 data for optic atrophy at AAO 2026

Stoke Therapeutics presented STK-002 data at the AAO 2026 Annual Meeting in New Orleans. STK-002 targets the underlying biology of Autosomal Dominant Optic Atrophy (ADOA). Dosing completed in first two cohorts of Phase 1 OSPREY study; third cohort ends by late 2026. Initial safety and efficacy data for higher-dose cohorts expected in H1 2027.

Stoke Therapeutics appoints Bo Cumbo to board ahead of drug approval

Bo Cumbo appointed to Stoke Therapeutics Board, replacing Edward Kaye, M.D. Appointment aims to enhance commercial expertise ahead of potential FDA approval in early 2028. Cumbo brings 30+ years experience, including leadership at Sarepta Therapeutics and Solid Biosciences. Lead drug zorevunersen holds Breakthrough Therapy and Orphan Drug designations from FDA.

Stoke Therapeutics grants stock options to nine new employees

Stoke Therapeutics granted stock options for 53,175 shares to nine new employees. Exercise price set at $28.15 per share, matching the September 15, 2026 closing price. Options vest over four years with a one-year cliff and monthly vesting thereafter. Grants comply with Nasdaq Listing Rule 5635(c)(4) as material employment inducements.

Stoke, Biogen report lasting seizure reductions in Dravet syndrome study

Stoke and Biogen presented 4-year OLE data on zorevunersen for Dravet syndrome. Data shows durable seizure reductions and cognitive improvements over 5+ years. Sub-analysis reveals reduction in severe seizures linked to SUDEP risk. Quality of life improved through 28 months of treatment in OLEs. Phase 3 EMPEROR trial enrollment ongoing with results expected in Q3 2027.

Stoke Therapeutics grants 70,950 stock options to seven new hires

Stoke Therapeutics granted 70,950 stock options to seven new employees at an exercise price of $32.13 per share. The grants, effective August 17, 2026, comply with Nasdaq Listing Rule 5635(c)(4) and vest over four years. This move supports recruitment for the biotechnology firm developing zorevunersen for Dravet syndrome.

Stoke Therapeutics Q2 Results: Sales beat estimates, EPS misses

Stoke Therapeutics delivered a mixed second-quarter performance, with sales of $9.325 million beating estimates by 54.27 percent. However, the company’s loss per share widened to $(0.93), missing the consensus estimate of $(0.80) and representing a 132.5 percent deterioration from the prior year’s $(0.40) loss. Total sales fell 32.51 percent year-over-year from $13.817 million.